LSE:SNG (Synairgen Plc)

Synairgen makes its annual accounts up to the 31 December of each year.

As per the 2020 annual report, Synairgen’s directors feel the groups model is to generate value through capital growth rather than payment of dividends. No dividend was proposed in the 2020 annual report nor the 2021 Interim report. Although the analyst consensus — which is from a single broker — is for dividends to be paid in the 2021 and 2022 fiscal years of 1.99p and 4.97p per share respectively, this fool feels this is unlikely.

Unlikely. No revenue has been reported since 2018, which related to the LOXL2 inhibitor program, and although it is involved in a phase two clinical trial, assuming it gets though this and all the way to market, any royalty income would be years away. A licensing agreement for SNG001 was a real possibility if the compound demonstrated success in its phase three clinical trial for hospital-based treatment of COVID-19, however, this trial was unsuccessful.